<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To describe the clinical outcome of refractory ocular <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease with adalimumab therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: Retrospective review of records </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Twenty-<z:mp ids='MP_0005163'>one eyes</z:mp> of 11 male patients with ocular <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease received adalimumab therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months </plain></SENT>
<SENT sid="4" pm="."><plain>Ten out of 11 patients showed complete resolution of <z:mp ids='MP_0001845'>inflammation</z:mp> by 4 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>The dosages of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>One patient on infliximab showed improvement of <z:mp ids='MP_0001845'>inflammation</z:mp> after switching over to adalimumab </plain></SENT>
<SENT sid="7" pm="."><plain>No serious side effects were observed in any of the patients </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Adalimumab appears to be effective in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
<SENT sid="9" pm="."><plain>It has been shown to improve visual acuity and also to have a <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> and immunosuppressive sparing effect </plain></SENT>
<SENT sid="10" pm="."><plain>It can induce and maintain sustained remission of the disease </plain></SENT>
</text></document>